Physicochemical and pharmacokinetic profiling of new chemical entities (NCEs) allows the rapid identification and elimination of compounds with properties not suitable for further development as drug candidates. Among the complex panel of theoretical and experimental methods available to predict or measure physicochemical or pharmacokinetic properties, some key techniques developed or tested in the pharmacochemistry group at EPGL are presented. This paper focuses on virtual and experimental approaches dealing with key properties such as ionization, solubility, lipophilicity, and membrane permeation. In addition, the effect of the third dimension on intramolecular interactions is exemplified by lipophilicity variations in the conformationa...
Many cyclic peptide natural products are larger and structurally more complex than conventional smal...
Peptides play a critical role in the life of organisms, performing completely different functions. T...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...
Physicochemical and pharmacokinetic profiling of new chemical entities (NCEs) allows the rapid ident...
To enhance the attrition rate of drug candidates a rapid identification and elimination of compounds...
The measurement of physicochemical properties at an early phase of drug discovery and development is...
Less than 2% of the lead compounds generated by the pharmaceutical industry enter the exploratory dr...
New effective experimental techniques in medicinal chemistry and pharmacology have resulted in a vas...
Lipophilicity and acid dissociation constants are important physicochemical properties that in part ...
[eng] According to ISO 17402:2008 more knowledge is needed on processes controlling bioavailability ...
An experimental/computational approach has been successfully applied in order to study the effect of...
Abstract Background Determination of lipophilicity as a tool for predicting pharmacokinetic molecula...
Noncovalent intermolecular associations are omnipresent in chemical and biochemical systems. Binding...
The Molecular Lipophilicity Potential (MLP) is a versatile tool in drug design whose present state a...
2013 Fall.Includes bibliographical references.This work evaluates the properties contributing to nat...
Many cyclic peptide natural products are larger and structurally more complex than conventional smal...
Peptides play a critical role in the life of organisms, performing completely different functions. T...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...
Physicochemical and pharmacokinetic profiling of new chemical entities (NCEs) allows the rapid ident...
To enhance the attrition rate of drug candidates a rapid identification and elimination of compounds...
The measurement of physicochemical properties at an early phase of drug discovery and development is...
Less than 2% of the lead compounds generated by the pharmaceutical industry enter the exploratory dr...
New effective experimental techniques in medicinal chemistry and pharmacology have resulted in a vas...
Lipophilicity and acid dissociation constants are important physicochemical properties that in part ...
[eng] According to ISO 17402:2008 more knowledge is needed on processes controlling bioavailability ...
An experimental/computational approach has been successfully applied in order to study the effect of...
Abstract Background Determination of lipophilicity as a tool for predicting pharmacokinetic molecula...
Noncovalent intermolecular associations are omnipresent in chemical and biochemical systems. Binding...
The Molecular Lipophilicity Potential (MLP) is a versatile tool in drug design whose present state a...
2013 Fall.Includes bibliographical references.This work evaluates the properties contributing to nat...
Many cyclic peptide natural products are larger and structurally more complex than conventional smal...
Peptides play a critical role in the life of organisms, performing completely different functions. T...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...